Post Marketing Assessment of the Efficacy and Safety of Netromax (Netilmicin) in the Indian Pediatric Population.

Objective: A post-marketing study of Netilmicin (Netromax™) in Indian pediatric patients to assess the safety and efficacy of the drug in various susceptible infections. Method: The study was carried out by 129 pediatricians from across India in 10 states (Maharashtra, Delhi, Uttar Pradesh, Andhra Pradesh, Odisha, Chhattisgarh, Karnataka, Madhya Pradesh, West Bengal, and Bihar) from November 2011 to February 2012. A total number of 542 case report forms were collected and considered eligible for further analysis based upon the completeness of data. The disease profile of patients included bacteremia, septicemia (including neonatal sepsis), severe respiratory tract infections (RTI), intra-abdominal infections (including peritonitis), kidney and genitourinary tract infections, skin and soft tissue infections, burns, bone and joint infections, wounds and perioperative infections. Result: Demographic analysis showed the median age of patients to be 13 months and median duration of therapy was 5 days. Intravenous route (IV) (n= 340) was preferred over intramuscular route (IM) (n=202) by the physicians. Netilmicin was administered in the therapeutic dose range depending upon the age and severity of the condition. The results revealed a favorable clinical efficacy and safety profile of Netilmicin. Clinical Improvement was observed in 98% (n=532) of patients among whom, clinical resolution (Defined as the absence of the infection) was achieved in 63% (n=343) patients. Whereas, partial improvement (defined as partial disappearance of original symptoms and no further requirement of antibiotics) was observed in 35% (n=189) of patients. Adverse events were reported in 11% of the entire study population and were mild in nature. There was no serious adverse event reported during the study period. Conclusion: The present post-marketing study confirmed that at the given doses and duration of therapy, NetromaxTM exhibited remarkable antibacterial efficacy with no serious incidences of toxicity. Thereby giving evidence that NetromaxTM treatment is safe and effective among the Indian pediatric population.

Aeromonas spp em diferentes pontos do fluxograma de beneficiamento do leite tipo A e susceptibilidade a antimicrobianos / Aeromonas spp in the line production of pasteurized type A milk and their antimicrobial susceptibility

Com o objetivo de verificar os possíveis pontos de contaminação e disseminação de bactérias do gênero Aeromonas em diferentes pontos do fluxograma de beneficiamento do leite tipo A, foram analisadas 120 amostras. Foi verificada a presença de Aeromonas spp. em 38 amostras, sendo identificadas as espécies A. sobria (40 por cento), A hydrophila (22 por cento), A. cavie (26 por cento), A. veronii (19 por cento) e A.schubertii (3 por cento). Das 37 amostras de espécies bacterianas avaliadas quanto à susceptibilidade aos antimicrobianos, foi observada múltipla resistência a drogas em 94 por cento das cepas testadas. As maiores sensibilidades foram observadas frente ao cloranfenicol, netilmicina, amicacina e gentamicina (80 por cento). A presença no leite das espécies deste gênero, comumente associadas com gastrenterites e as altas resistências observadas frente a múltiplos princípios ativos, devem ser levadas em consideração, pois podem representar um sério risco para a saúde dos consumidores, na eventual necessidade da instituição de um regime terapêutico em casos de infecção por Aeromonas spp.

Invitro comparative evaluation of aminoglycosides at a cancer centre.

A comparative study of in vitro activity of amikacin, gentamicin, netilmicin, tobramycin and isepamicin was done. A total of 200 clinical isolates of Gram negative organisms from various clinical sources were tested. E.Coli was the most frequently isolated organism followed by Pseudomonas spp., Klebsiella spp., Proteus spp., Acinetobacter spp. and Enterobacter spp. Of the 5 aminoglycosides tested, isepamicin showed the highest numbers of susceptible isolates followed by amikacin, netilmicin, gentamicin and tobramycin. MIC 90 value of isepamicin was lower as compared to amikacin.

In vitro activity of netilmicin against clinical isolates of methicillin resistant and susceptible Staphylococcus aureus.

BACKGROUND: The emergence of methicillin-resistant Staphylococcus aureus and its multidrug-resistant property has led to the search for an effective antibiotic to combat staphylococcal sepsis. At present, vancomycin remains the most effective antibiotic. This study evaluated the in vitro efficacy of netilmicin (an aminoglycoside) and compared its activity with 4 other antibiotics, viz. vancomycin, amikacin, tobramycin and ofloxacin. METHODS: The minimum inhibitory concentration of the antibiotics was determined by the agar dilution method. Thirty strains each of methicillin-resistant and -susceptible S. aureus isolated from pus and blood cultures were included. RESULTS: The susceptibility to netilmicin was found to be 100% and was the same as that observed for vancomycin. CONCLUSION: All the methicillin-resistant S. aureus strains tested showed 100% susceptibility to netilmicin, suggesting its use in patients with such infections as an alternative to vancomycin. However, this finding needs to be verified in the clinical setting.

In vitro synergistic activity of cefotaxime and netilmicin against pseudomonas aeruginosa strains

Twenty multiresistant Ps. aeruginosa strains were serotyped and subjected to a combination of two antibiotics, cefotaxime and netilmicin, using the Checker board broth dilution method, over a concentration ranging from 250 - 3.9 ug/ml. Synergism was observed between the two antibiotics against 18 of the 20 tested strains. The clinical significance of this in vitro synergy must be ultimately determined by carefully conducted comparative clinical trials